Following Marty Makary's resignation as FDA commissioner earlier this month, President Trump appointed Kyle Diamantas as acting commissioner. Diamantas, previously the deputy overseeing the agency's food program with longstanding administration ties, now holds the interim role amid Senate confirmation requirements for any permanent successor. This immediate elevation has driven trader consensus toward Diamantas at 53% implied probability, reflecting the practical edge of acting status and White House endorsement in filling the vacancy. The 11.6% probability attached to no announcement by December 31 incorporates potential delays in the confirmation process, while lower odds for figures such as Stephen Hahn and Brett Giroir align with their comparatively limited recent visibility in administration health policy discussions.
สรุปจาก AI ทดลองที่อ้างอิงข้อมูลจาก Polymarket ไม่ใช่คำแนะนำในการเทรดและไม่มีผลต่อการตัดสินตลาดนี้ · อัปเดตแล้วKyle Diamantas 52%
No announcement by December 31 13.9%
Stephen Hahn 4%
Brett Giroir 3.9%
ใหม่
ใหม่
Dec 31, 2026
Kyle Diamantas
52%
Stephen Hahn
4%
Brett Giroir
4%
Grace Graham
3%
Sara Brenner
3%
No announcement by December 31
14%
Kyle Diamantas 52%
No announcement by December 31 13.9%
Stephen Hahn 4%
Brett Giroir 3.9%
ใหม่
ใหม่
Dec 31, 2026
Kyle Diamantas
$1,525 ปริมาณ
52%
Stephen Hahn
$976 ปริมาณ
4%
Brett Giroir
$1,510 ปริมาณ
4%
Grace Graham
$1,893 ปริมาณ
3%
Sara Brenner
$849 ปริมาณ
3%
No announcement by December 31
$533 ปริมาณ
14%
This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.Following Marty Makary's resignation as FDA commissioner earlier this month, President Trump appointed Kyle Diamantas as acting commissioner. Diamantas, previously the deputy overseeing the agency's food program with longstanding administration ties, now holds the interim role amid Senate confirmation requirements for any permanent successor. This immediate elevation has driven trader consensus toward Diamantas at 53% implied probability, reflecting the practical edge of acting status and White House endorsement in filling the vacancy. The 11.6% probability attached to no announcement by December 31 incorporates potential delays in the confirmation process, while lower odds for figures such as Stephen Hahn and Brett Giroir align with their comparatively limited recent visibility in administration health policy discussions.
This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
ตลาดเปิดเมื่อ: May 12, 2026, 7:59 PM ET
ปริมาณการซื้อขาย
$7,286วันสิ้นสุด
Dec 31, 2026ตลาดเปิดเมื่อ
May 12, 2026, 7:59 PM ETResolver
0x69c47De9D...This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.Following Marty Makary's resignation as FDA commissioner earlier this month, President Trump appointed Kyle Diamantas as acting commissioner. Diamantas, previously the deputy overseeing the agency's food program with longstanding administration ties, now holds the interim role amid Senate confirmation requirements for any permanent successor. This immediate elevation has driven trader consensus toward Diamantas at 53% implied probability, reflecting the practical edge of acting status and White House endorsement in filling the vacancy. The 11.6% probability attached to no announcement by December 31 incorporates potential delays in the confirmation process, while lower odds for figures such as Stephen Hahn and Brett Giroir align with their comparatively limited recent visibility in administration health policy discussions.
This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
ปริมาณการซื้อขาย
$7,286วันสิ้นสุด
Dec 31, 2026ตลาดเปิดเมื่อ
May 12, 2026, 7:59 PM ETResolver
0x69c47De9D...Following Marty Makary's resignation as FDA commissioner earlier this month, President Trump appointed Kyle Diamantas as acting commissioner. Diamantas, previously the deputy overseeing the agency's food program with longstanding administration ties, now holds the interim role amid Senate confirmation requirements for any permanent successor. This immediate elevation has driven trader consensus toward Diamantas at 53% implied probability, reflecting the practical edge of acting status and White House endorsement in filling the vacancy. The 11.6% probability attached to no announcement by December 31 incorporates potential delays in the confirmation process, while lower odds for figures such as Stephen Hahn and Brett Giroir align with their comparatively limited recent visibility in administration health policy discussions.
สรุปจาก AI ทดลองที่อ้างอิงข้อมูลจาก Polymarket ไม่ใช่คำแนะนำในการเทรดและไม่มีผลต่อการตัดสินตลาดนี้ · อัปเดตแล้ว
ระวังลิงก์ภายนอก
ระวังลิงก์ภายนอก
คำถามที่พบบ่อย